Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day: Prospective study of immunogenicity to SARS-CoV-2 boosters in myeloma and Waldenström finds factors associated with lower response were: hypogamma, lymphopenia, anti-CD38, corticosteroid in MM; anti-CD20 or BTKi therapy 4 WM.”
Title: Prospective study of immunogenicity to SARS-CoV-2 booster vaccines in multiple myeloma and Waldenström macroglobulinemia
Authors: Andrew R. Branagan, Clifton C Mo, Matthew M Lei, Joshua Gustine, Andrew J. Yee, Elizabeth O’Donnell, Jorge J. Castillo, Omar Nadeem, Catherine Flynn, Zachary Bernstein, Rie Nakamoto-Matsubara, Kirsten E. Meid, Rakesh Verma, Zachary R Hunter, Maria Luisa Guerrera, Galit Alter, Jill N. Burke, Cynthia C. Harrington, Emerentia A. Agyemang, Marilyn T. Gammon, Kathleen J. Lively, Lisette Packer, Nora Horick, Jacob P Laubach, Constantine S. Mitsiades, Nikhil C. Munshi, Kenneth C. Anderson, Steven P. Treon, Paul G Richardson, Noopur S. Raje, Shayna Sarosiek
You can read the Full Article in Blood.
More posts featuring Robert Orlowski.
